IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, May 2025
Impact Factor: 7.67

Fast Dissolving Tablets: A Novel Approach in Oral Drug Delivery

Mr. Prajwal Vilas Kusare and Dr. Pankaj M. Pimpalshende
Hi-Tech College of Pharmacy, Morwa, Chandrapur, India

Abstract: *Fast Dissolving Tablets (FDTs) represent a novel and promising approach in oral drug delivery, designed to rapidly dissolve or disintegrate in the mouth without the need for water. This drug delivery system provides significant benefits over conventional tablets and capsules, including improved patient compliance, especially for pediatric, geriatric, and dysphagic patients. FDTs are designed to enhance the solubility, bioavailability, and onset of action of various drugs, making them ideal for conditions requiring rapid therapeutic intervention. The formulation of FDTs involves innovative techniques such as direct compression, lyophilization, sublimation, and spray drying, aimed at achieving rapid disintegration while maintaining mechanical strength and stability. These tablets offer an ideal solution for patients who have difficulty swallowing, providing ease of administration and enhancing the patient experience. However, challenges remain in terms of taste masking, moisture sensitivity, and mechanical strength. Recent advancements in nanotechnology, 3D printing, and personalized medicine are expected to further improve the efficacy and customization of FDT formulations. Additionally, evolving regulatory frameworks are essential for ensuring the safety, efficacy, and consistency of these novel formulations. This review highlights the key aspects of FDT development, including formulation strategies, evaluation methods, and emerging trends, while also discussing their clinical applications, advantages, limitations, and future prospects in the pharmaceutical industry.*

Keywords: Fast Dissolving Tablets, Oral Drug Delivery, Patient Compliance, Drug Release, Nanotechnology, 3D Printing, Formulation Techniques, Personalized Medicine

I. INTRODUCTION

Definition and Significance of Fast Dissolving Tablets (FDTs)

Fast Dissolving Tablets (FDTs), also referred to as Orally Disintegrating Tablets (ODTs), are solid dosage forms that disintegrate or dissolve rapidly in the mouth, typically within a few seconds to a minute, without the need for water. These tablets are designed to break down upon contact with saliva, allowing the drug to be swallowed easily or absorbed partially through the oral mucosa. According to the United States Food and Drug Administration (US FDA), an orally disintegrating tablet is "a solid dosage form containing medicinal substances which disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue." This feature makes FDTs especially advantageous for patient populations who face difficulties in swallowing conventional oral solid dosage forms, such as pediatric, geriatric, bedridden, and mentally ill patients.

The significance of FDTs lies in their potential to enhance patient compliance and convenience. By eliminating the need for water and offering a fast onset of action, FDTs are particularly suitable for situations requiring immediate therapeutic intervention, such as allergic reactions, migraines, and pain management. Moreover, FDTs can improve bioavailability by avoiding first-pass metabolism when the drug is absorbed through the buccal or sublingual route. This delivery system also facilitates ease of administration in travel or emergency settings where water may not be readily available. From a commercial perspective, FDTs represent a growing segment in the pharmaceutical market, with ongoing innovations in formulation technologies, such as lyophilization, direct compression, and spray drying, enabling the development of robust, palatable, and stable products. Overall, FDTs are an important advancement in oral drug delivery, aligning with the industry's shift towards patient-centric and user-friendly dosage forms.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, May 2025
Impact Factor: 7.67

Advantages Over Conventional Tablets and Capsules

Fast Dissolving Tablets (FDTs) offer several distinct advantages over conventional tablets and capsules, primarily centered around enhanced patient compliance and convenience. One of the most significant benefits is the **elimination of the need for water** during administration. This feature makes FDTs highly suitable for pediatric, geriatric, and dysphagic patients who may have difficulty swallowing solid dosage forms. In contrast, conventional tablets and capsules often require water for ingestion, which can be a limiting factor in emergency or travel situations where water may not be readily available.

Another key advantage is the **rapid onset of action**. Since FDTs disintegrate and dissolve quickly in the oral cavity, the drug can be absorbed either through the mucosal lining or rapidly enter the gastrointestinal tract, leading to quicker therapeutic effects. This is particularly beneficial in conditions requiring immediate relief, such as acute pain, allergic reactions, or anxiety.

FDTs also contribute to **improved bioavailability** in some cases by partially bypassing the first-pass hepatic metabolism when absorbed through the buccal or sublingual mucosa. Moreover, they are **convenient to administer without the need for dosing aids**, making them ideal for on-the-go use, and reducing the risk of dose omission, especially in patients with cognitive impairments.

From a pharmaceutical standpoint, FDTs offer **flexibility in formulation design**, allowing for the incorporation of taste-masking agents and flavoring substances to enhance palatability—an essential factor in pediatric and geriatric therapy. The patient-centric design of FDTs aligns with modern healthcare goals of improving adherence, optimizing treatment outcomes, and minimizing medication-related complications.

Overall, the advantages of FDTs over traditional oral solid dosage forms underscore their growing importance in both clinical practice and pharmaceutical development.

Target Populations (Pediatrics, Geriatrics, Dysphagic Patients)

Fast Dissolving Tablets (FDTs) are specifically designed to address the needs of patient populations who face challenges with conventional oral dosage forms, particularly **pediatric, geriatric, and dysphagic patients**. Children, especially infants and toddlers, often have difficulty swallowing tablets and capsules, and they may exhibit resistance to taking bitter-tasting or unpalatable medicines. FDTs provide a child-friendly alternative that dissolves quickly in the mouth, often with added flavors and sweeteners to improve palatability. This not only enhances compliance but also reduces the risk of choking, a common concern among caregivers and healthcare providers.

In the **geriatric population**, physiological changes associated with aging, such as reduced salivary secretion, weakening of esophageal muscles, and cognitive decline, often contribute to swallowing difficulties. These patients may also suffer from multiple chronic conditions requiring polypharmacy, which can make medication management complex and burdensome. FDTs offer a simplified and safer mode of drug administration, enabling elderly individuals to take their medications without the need for water and with minimal effort, thereby improving adherence and therapeutic outcomes.

Dysphagic patients, including those with neurological disorders (e.g., Parkinson's disease, Alzheimer's disease, stroke), head and neck cancer, or post-surgical complications, are another critical group that benefits from FDTs. These individuals are at high risk of aspiration when swallowing traditional tablets, which can lead to serious complications such as aspiration pneumonia. The use of FDTs minimizes this risk by eliminating the swallowing requirement and providing a safer and more acceptable dosage form.

Overall, the development and use of FDTs are driven by the need to cater to these vulnerable populations, aligning with the principles of patient-centric drug design and personalized medicine. Their ease of use, safety profile, and rapid therapeutic action make them an invaluable option for individuals with compromised swallowing abilities.

II. SCOPE AND OBJECTIVES OF THE REVIEW

The scope of this review encompasses a comprehensive examination of fast dissolving tablet (FDT) technology, with a focus on its evolution, formulation, evaluation, and therapeutic applications. As a rapidly expanding field within oral drug delivery systems, FDTs represent a significant advancement aimed at improving patient compliance and achieving prompt pharmacological effects. The review covers the key aspects of FDTs, including their definition, historical

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, May 2025
Impact Factor: 7.67

background, target populations, advantages over traditional dosage forms, formulation strategies, manufacturing techniques, evaluation parameters, regulatory perspectives, and recent advancements. It also touches upon the challenges and limitations associated with FDT development and highlights areas for future research and innovation.

The primary objectives of this review are threefold: first, to **analyze the scientific and technological advancements** that have contributed to the development and optimization of FDTs; second, to **discuss the critical formulation components and methodologies** that influence the performance and stability of FDTs; and third, to **explore their clinical and commercial relevance**, particularly in addressing the unmet needs of patient populations with swallowing difficulties. Additionally, the review aims to serve as a resource for pharmaceutical scientists, researchers, and healthcare professionals seeking to understand the current trends, regulatory requirements, and formulation challenges associated with FDTs. By consolidating existing knowledge and highlighting ongoing research directions, this review aspires to foster innovation and guide the rational design of patient-friendly and therapeutically effective FDT formulations.

III. HISTORICAL BACKGROUND AND MARKET OVERVIEW

Evolution of FDTs

The development of Fast Dissolving Tablets (FDTs) marks a significant milestone in oral drug delivery systems, evolving from the need to enhance patient compliance and convenience. The concept of FDTs first gained traction in the early 1990s, driven by the desire to overcome the limitations of conventional tablets and capsules, especially in patient groups who experience difficulty swallowing. Initial approaches relied on lyophilization (freeze-drying), where porous structures facilitated rapid disintegration in the mouth. This was followed by the advent of other techniques such as direct compression and spray-drying, which simplified production processes and improved the mechanical strength of the tablets. Over the past three decades, advances in excipient technology and formulation science have led to the development of more robust and palatable FDTs with improved drug loading and stability profiles. The evolution of FDTs has been closely tied to growing awareness of patient-centric drug design and the increasing demand for safer, more accessible dosage forms.

Regulatory Definitions (FDA, EMA)

Regulatory agencies such as the United States Food and Drug Administration (US FDA) and the European Medicines Agency (EMA) have recognized and defined orally disintegrating tablets to ensure consistency in formulation and evaluation standards. According to the US FDA, an orally disintegrating tablet is “a solid dosage form containing medicinal substances which disintegrates rapidly, usually within seconds, when placed upon the tongue.” The EMA similarly defines these formulations as tablets intended to disintegrate or dissolve rapidly in the mouth without the need for water, generally within 30 seconds. These definitions have guided formulation scientists in developing products that meet regulatory expectations for disintegration time, mechanical strength, palatability, and overall product quality. Regulatory frameworks also provide guidance on clinical testing, bioequivalence, and labeling requirements specific to FDTs.

IV. MARKETED PRODUCTS AND GLOBAL MARKET TRENDS

The commercial success of FDTs is evident from the wide range of products available globally across various therapeutic categories, including analgesics, antihistamines, antipsychotics, antiemetics, and cardiovascular agents. Notable examples include *Zofran ODT*® (ondansetron), *Claritin RediTabs*® (loratadine), *Maxalt-MLT*® (rizatriptan), and *Zyprexa Zydis*® (olanzapine), which have set benchmarks in FDT innovation and commercial viability. The global FDT market has witnessed exponential growth, fueled by technological advancements, increased prevalence of chronic diseases, and a shift toward patient-centric drug delivery systems. According to market analysis reports, the FDT market is expected to grow at a compound annual growth rate (CAGR) of over 6% in the coming years, driven by increased demand in both developed and emerging economies. Pharmaceutical companies are also investing heavily in research and development to expand their FDT product pipelines and to explore novel drug candidates suitable for this

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, May 2025
Impact Factor: 7.67

dosage form. The market expansion is further supported by patent expirations of blockbuster drugs, encouraging the development of generic FDTs and fixed-dose combinations.

V. FORMULATION ASPECTS

5.1. Drug Selection Criteria

The selection of an appropriate drug for Fast Dissolving Tablets (FDTs) is a critical step in ensuring the success of the formulation. Several factors must be considered to optimize both the therapeutic efficacy and the patient experience. Among these, the physicochemical properties of the drug and any dose limitations are two of the most crucial criteria.

Physicochemical Properties

The physicochemical properties of a drug are fundamental to its suitability for FDT formulation. The following characteristics must be carefully evaluated:

1. **Solubility**: For FDTs to exhibit rapid disintegration and effective drug release, the active pharmaceutical ingredient (API) must have adequate solubility in saliva or the gastrointestinal fluid. Poorly water-soluble drugs may require formulation strategies to enhance solubility, such as the inclusion of solubilizing agents, surfactants, or using technologies like solid dispersions.
2. **Particle Size**: The particle size of the drug can significantly influence the disintegration and dissolution rate of the tablet. Smaller particles tend to dissolve more quickly, leading to faster onset of action. However, achieving the ideal particle size requires careful consideration to avoid issues like aggregation or caking, which could hinder dissolution.
3. **Stability**: The stability of the drug under the conditions typical for FDTs, including exposure to moisture and temperature variations, is essential. Drugs with a tendency to degrade when exposed to environmental factors may not be suitable for FDT formulation unless special stability-enhancing techniques are applied (e.g., encapsulation or stabilization with excipients).
4. **Taste and Sensory Attributes**: Many drugs have an unpleasant taste, which can be challenging in FDTs that dissolve in the mouth. Drugs with bitter or astringent tastes may require the use of taste-masking agents such as polymer coatings or inclusion complexes (e.g., cyclodextrins) to make them palatable for the patient.
5. **Molecular Weight**: Higher molecular weight drugs may face challenges in rapid absorption, so the formulation may need to include excipients that aid in permeation across the mucosal membranes or enhance bioavailability.
6. **Lipophilicity**: Drugs with high lipophilicity may have poor aqueous solubility, which can hinder rapid dissolution in the mouth. In such cases, formulation strategies such as the use of surfactants, lipid carriers, or microemulsions may be employed to improve drug solubility and enhance the dissolution rate.

Dose Limitations

The dose of the drug plays a significant role in determining the practicality and effectiveness of its formulation as an FDT. Key considerations related to dose limitations include:

1. **High-Dose Drugs**: For drugs that require high dosages, the size of the tablet may become a limiting factor. A large tablet can compromise the rapid disintegration and the convenience of administration, particularly for pediatric or geriatric patients. In such cases, FDTs may need to be formulated with alternative drug delivery technologies, such as controlled-release systems, or with reduced doses to fit within the constraints of tablet size.
2. **Potent Drugs**: Highly potent drugs with low therapeutic doses present a challenge, as even small deviations in dose can lead to adverse effects. The precision in dose delivery, as well as the uniformity of drug distribution within the FDT, is crucial to avoid potential toxicity or ineffective therapy. In these cases, careful selection of excipients that aid in accurate dosing and uniform drug distribution is essential.
3. **Taste and Dose Proportions**: The dose of the drug also affects the ability to mask unpleasant tastes, as higher doses typically result in a greater quantity of active ingredient to mask. In such cases, taste-masking technologies need to be more sophisticated to ensure the final product remains palatable.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, May 2025
Impact Factor: 7.67

4. **Drug Release Profile**: The dose of the drug also impacts the intended release profile. Drugs with high doses or extended-release requirements may not be suitable for FDT formulations due to their need for prolonged dissolution times, which contradict the rapid dissolution characteristics of FDTs. Alternatively, for drugs with immediate-release requirements, lower-dose formulations tend to be more appropriate for FDT development.

The selection of the drug for FDT formulation must balance several critical physicochemical properties and dose-related considerations. By carefully evaluating these factors, formulators can create FDTs that offer enhanced bioavailability, patient adherence, and therapeutic efficacy.

5.2. Excipients Used in Fast Dissolving Tablets

The formulation of Fast Dissolving Tablets (FDTs) involves the use of a range of excipients that play a crucial role in achieving rapid disintegration, enhancing drug release, and improving the overall patient experience. These excipients must be carefully selected based on their functionality and compatibility with the active pharmaceutical ingredients (APIs). The key excipients used in FDT formulations include superdisintegrants, fillers, sweeteners, flavors, taste-masking agents, binders, and lubricants.

Superdis integrants

Superdisintegrants are one of the most important excipients in FDT formulations because they facilitate the rapid disintegration of the tablet when it comes into contact with saliva. These excipients help the tablet break apart into smaller fragments, allowing for faster dissolution and drug release. The following superdisintegrants are commonly used in FDT formulations:

1. **Crospovidone**: Crospovidone is a cross-linked polyvinylpyrrolidone that absorbs water quickly, swells, and creates a network that helps the tablet disintegrate rapidly. It has high efficiency at low concentrations, making it one of the most widely used superdisintegrants for FDTs. Its use enhances the disintegration time without compromising the mechanical strength of the tablet.
2. **Croscarmellose Sodium**: This is a sodium cross-linked polymer of carboxymethylcellulose. It swells upon absorbing water and helps break down the tablet structure. Croscarmellose sodium is known for its rapid disintegration properties, which are crucial for FDTs that require a swift onset of drug action. It is also widely used in combination with other disintegrants to achieve an optimal release profile.
3. **Sodium Starch Glycolate**: Sodium starch glycolate is a highly effective superdisintegrant derived from starch. It exhibits high swelling and disintegration properties in the presence of water. It is particularly useful in FDT formulations that require a very quick onset of disintegration and is often used for water-sensitive drugs.

These superdisintegrants are critical to achieving the rapid disintegration characteristic of FDTs, ensuring that the tablets dissolve almost immediately upon contact with the tongue.

Fillers

Fillers or diluents are used to add bulk to FDT formulations, making the tablets easier to handle and ensuring that they maintain a proper size for administration. They also play a role in enhancing the mouthfeel of the tablets. Common fillers include:

1. **Mannitol**: Mannitol is a sugar alcohol commonly used as a filler in FDTs. It is a versatile excipient that provides a smooth texture, a cooling effect upon dissolution, and excellent mouthfeel. Additionally, it is less hygroscopic, making it suitable for formulations that require long-term stability. Mannitol also imparts a slightly sweet taste, which can enhance the palatability of the tablet.
2. **Lactose**: Lactose is another common filler in tablet formulations. It provides bulk to the tablets, contributing to their mechanical strength. While lactose is widely used, its use in FDTs may be limited for patients with lactose intolerance. For these patients, alternatives like mannitol or xylitol are preferred.

Fillers are essential in ensuring that the tablet has an appropriate size, stability, and texture, while also contributing to the overall formulation's ability to rapidly dissolve in the mouth.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, May 2025
Impact Factor: 7.67

Sweeteners, Flavors, and Taste-Masking Agents

Given that FDTs dissolve in the mouth, the taste of the tablet becomes an important factor in patient compliance, especially for pediatric and geriatric populations. To improve the acceptability of the tablets, sweeteners, flavors, and taste-masking agents are used.

1. **Sweeteners**: Non-caloric sweeteners like aspartame, saccharin, and sucralose are commonly used to mask the bitter taste of the API and improve the palatability of FDTs. These sweeteners are carefully chosen to provide a sweet taste without adding excessive calories or negatively impacting the stability of the formulation.
2. **Flavors**: Flavoring agents, such as fruit flavors (e.g., orange, strawberry, or mint), are added to improve the overall sensory experience of the tablet. These flavors mask any residual taste of the API, improving the patient's compliance with the therapy.
3. **Taste-Masking Agents**: Bitter drugs often require special formulations to mask their taste. Techniques such as coating the API with polymers (e.g., ethylcellulose or hydroxypropyl methylcellulose) or inclusion complexation with cyclodextrins are commonly employed to create a barrier between the drug and taste receptors on the tongue. These taste-masking agents ensure that the FDT remains palatable during its rapid disintegration.

Binders and Lubricants

Binders and lubricants are used to enhance the mechanical properties of FDTs and ensure smooth tablet formation and processing.

1. **Binders**: Binders help to hold the tablet ingredients together and provide necessary strength to the tablet. In FDTs, binders must be carefully selected to avoid hindering rapid disintegration. Common binders used in FDT formulations include:
    - **Hydroxypropyl Methylcellulose (HPMC)**: A widely used binder that also contributes to the tablet's disintegration. It forms a gel when in contact with water, aiding in rapid dissolution.
    - **Polyvinylpyrrolidone (PVP)**: A water-soluble binder that provides good adhesive properties and stability. It is often used in combination with superdisintegrants to optimize disintegration.
2. **Lubricants**: Lubricants are used to reduce friction during tablet compression and ensure smooth tablet ejection from the die. Common lubricants used in FDT formulations include:
    - **Magnesium Stearate**: The most widely used lubricant in tablet formulations. It reduces friction between the tablet and the compression machine, ensuring a smooth and uniform tablet.
    - **Stearic Acid**: Another lubricant that helps improve the flowability of powders during tablet formation.

Both binders and lubricants play a crucial role in the manufacturing of FDTs, ensuring that the tablets are cohesive, stable, and easy to handle during production without compromising their disintegration rate.

In summary, excipients in FDT formulations play vital roles in ensuring rapid disintegration, pleasant taste, adequate tablet size, and overall product stability. By carefully selecting excipients such as superdisintegrants, fillers, sweeteners, and binders, formulators can achieve optimal performance and patient compliance for FDTs.

VI. TECHNIQUES USED IN THE PREPARATION OF FDTS

The preparation of Fast Dissolving Tablets (FDTs) involves the application of various techniques to ensure rapid disintegration, effective drug release, and optimal patient acceptability. Several manufacturing methods are employed, each offering unique advantages for different types of drugs and excipient combinations. The most commonly used techniques for preparing FDTs include direct compression, lyophilization (freeze-drying), molding, sublimation, spray drying, and mass extrusion.

6.1. Direct Compression

Direct compression is the most commonly used and simplest technique for preparing FDTs. In this method, the active pharmaceutical ingredient (API) and excipients are mixed together and compressed into tablets without the need for a

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, May 2025
Impact Factor: 7.67

solvent or heat. The steps involved in direct compression typically include blending, compacting, and tablet formation. This method is particularly beneficial for drugs that are sensitive to heat or moisture.

Advantages:

- **Simplicity**: Direct compression is a simple, cost-effective process that requires minimal equipment.
- **Preservation of drug stability**: Since no heat or solvents are involved, the drug is not exposed to conditions that could affect its stability.
- **Faster manufacturing**: The process is quick, making it ideal for large-scale production.
- **Suitable for heat-sensitive drugs**: Drugs that are unstable when exposed to heat or moisture can be easily incorporated into FDT formulations using direct compression.

However, one limitation of this technique is that it may not be suitable for drugs that require specific solubility enhancements or have poor flow properties. In such cases, additional steps like the use of superdisintegrants or alternative excipients may be necessary.

6.2. Lyophilization (Freeze-Drying)

Lyophilization, or freeze-drying, is a technique that involves the removal of water from a drug formulation through sublimation, where the drug is first frozen and then subjected to reduced pressure to remove the ice as vapor. This results in a porous structure that dissolves rapidly when it comes into contact with moisture, making it ideal for FDTs.

Process:

1. The drug solution or suspension is prepared.
2. The solution is frozen at low temperatures.
3. The frozen drug is then subjected to vacuum pressure, causing the water to sublimate, leaving behind a dried porous matrix.

Advantages:

- **Enhanced disintegration and dissolution**: The porous structure produced by lyophilization allows for very rapid disintegration and dissolution, which is a key feature of FDTs.
- **Improved stability**: Freeze-drying helps preserve the stability of heat-sensitive drugs.
- **Higher drug loading**: Lyophilization can accommodate a larger dose of drug without compromising the tablet's rapid disintegration properties.

However, lyophilization can be an expensive process due to the need for specialized equipment and the long drying times required.

6.3. Molding

Molding is another technique used to prepare FDTs, where the formulation is poured into pre-designed molds and then allowed to harden. Molds can be made from materials like plastic, rubber, or stainless steel, and the process may involve wet granulation or compression of the formulation into mold cavities. The key feature of molded FDTs is their ability to be tailored to specific shapes and sizes.

Advantages:

- **Customization**: Molding allows for precise control over the tablet's shape and size, which can be advantageous for patient acceptance, particularly for pediatric or geriatric populations.
- **Rapid dissolution**: Molded FDTs are often highly porous, promoting quick disintegration when placed in the mouth.
- **No need for heat**: The molding process generally avoids the need for high heat, making it suitable for heat-sensitive drugs.

Despite these advantages, molding can be time-consuming and may involve complex equipment. Additionally, the tablets formed may have lower mechanical strength compared to those produced by compression techniques.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, May 2025
Impact Factor: 7.67

6.4. Sublimation

Sublimation involves the use of volatile materials that can be incorporated into the tablet mass. During the preparation, these volatile components are mixed with the drug and excipients. After tablet compression, the volatile component is removed through sublimation (transitioning from a solid to a gas without passing through a liquid state) under controlled conditions. This creates a porous structure within the tablet, aiding in rapid disintegration.

Process:

1. The drug is mixed with excipients and sublimable substances (such as camphor or ammonium bicarbonate).
2. The mixture is compressed into tablet form.
3. The tablets are subjected to heat under reduced pressure, causing the sublimable substances to vaporize, leaving behind a porous structure.

Advantages:

- **Porous structure**: The sublimation process creates a tablet with a highly porous structure, resulting in fast dissolution.
- **Rapid disintegration**: The removal of the volatile substance leaves behind a tablet that can break apart quickly when exposed to moisture.
- **No need for excessive binder or lubricant**: The removal of volatile substances minimizes the need for additional excipients that could potentially hinder disintegration.

However, the choice of sublimable material is important, as it must be compatible with the drug and excipients. Additionally, sublimation can be more complex than other methods and requires specific equipment for the controlled heating process.

6.5. Spray Drying

Spray drying is a technique in which a drug formulation is converted into a dry powder by spraying it into a hot air stream. This process involves atomizing the drug-excipient mixture into fine droplets that quickly dry and solidify. The resulting dry particles are then used to form FDTs.

Process:

1. The drug and excipients are dissolved or suspended in a liquid phase.
2. The liquid is sprayed into a hot air chamber, where the solvent evaporates rapidly, leaving behind dry drug particles.
3. These particles are collected and can be directly compressed into tablets or used in other formulations.

Advantages:

- **Uniform drug distribution**: Spray drying ensures a homogeneous distribution of the drug within the formulation, which can enhance bioavailability and improve dissolution rates.
- **Enhanced solubility**: The technique can improve the solubility of poorly water-soluble drugs by converting them into amorphous forms or increasing their surface area.
- **Efficient for large-scale production**: Spray drying is a scalable technique suitable for mass production.

Despite its advantages, spray drying may not be suitable for all drugs, especially those sensitive to high temperatures, as the drying process can expose them to heat.

6.6. Mass Extrusion

Mass extrusion involves the use of a process where the drug-excipient blend is extruded through a die to form a continuous strand, which is then cut into tablet sizes. This method is particularly useful for drugs with low compression characteristics or drugs that require a high dose but are sensitive to compression.

Process:

1. The drug and excipients are mixed together and heated to a malleable state.
2. The mixture is extruded through a die to form long strands.
3. The strands are then cut into tablet-sized pieces and allowed to cool and solidify.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, May 2025
Impact Factor: 7.67

Advantages:

- **Uniform drug distribution**: Mass extrusion provides excellent mixing of the drug and excipients, ensuring consistent content uniformity.
- **Suitable for heat-sensitive drugs**: Since the process does not involve direct compression, it is suitable for heat-sensitive or thermolabile drugs.
- **Improved mechanical properties**: The process allows for the development of tablets with good mechanical strength, which can withstand handling and transportation.

However, mass extrusion may not be suitable for drugs that do not easily form cohesive mixtures or require specialized excipients.

The choice of technique for the preparation of Fast Dissolving Tablets is determined by the specific requirements of the drug and the desired characteristics of the final product. Each of the techniques, including direct compression, lyophilization, molding, sublimation, spray drying, and mass extrusion, offers distinct advantages that can be tailored to the formulation's needs. A careful selection of the method, based on factors such as the drug's physicochemical properties, stability, and patient population, ensures the creation of effective and patient-friendly FDTs.

VII. EVALUATION AND CHARACTERIZATION OF FDTS

The evaluation and characterization of Fast Dissolving Tablets (FDTs) are crucial to ensuring their quality, safety, and efficacy. Various in vitro tests and procedures are employed to assess the performance of these tablets under conditions simulating their use. Below are the key parameters used to evaluate FDTs.

7.1. Weight Variation

Weight variation is an important quality control test for FDTs to ensure that the tablets contain the correct amount of active pharmaceutical ingredient (API) and excipients. Uniform weight across the tablets in a batch is essential for consistent dosing.

Procedure:

- Randomly select a specific number of tablets from each batch (typically 20 tablets).
- Weigh each tablet individually and calculate the average weight.
- The weight variation is determined by comparing the individual tablet weights to the average weight. If the difference exceeds a predefined percentage limit (often within 5-7% of the average weight), the batch may not be acceptable.

Significance:

- Ensures uniformity of drug dosage across all tablets.
- Prevents the risk of under or over-dosing patients due to weight discrepancies.

7.2. Friability and Hardness

Friability and hardness tests assess the mechanical strength and resistance of FDTs to breaking, chipping, or cracking during handling and transportation. These properties are particularly important for FDTs because they should disintegrate quickly when placed in the mouth without being too fragile or too hard.

Friability Test:

- A sample of 20 tablets is placed in a rotating drum (friabilator) and subjected to a specific number of rotations (typically 100 revolutions at 25 rpm).
- After the test, the tablets are reweighed, and the percentage loss in weight is calculated.
- A friability value of less than 1% is generally considered acceptable for FDTs.

Hardness Test:

- The hardness of FDTs is measured using a hardness tester that applies force to the tablet until it fractures.
- The required hardness for FDTs is typically lower than conventional tablets because they need to disintegrate quickly but should not be too brittle to handle.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, May 2025
Impact Factor: 7.67

Significance:

- A low friability ensures that the tablet does not break or lose significant weight during transportation and handling.
- Adequate hardness ensures the tablet has sufficient mechanical strength to withstand normal handling but can still break down rapidly in the mouth.

7.3. Disintegration Time

Disintegration time refers to the time required for the tablet to break down into small particles when exposed to a specific fluid, usually simulated saliva or water. For FDTs, this test is critical because rapid disintegration is essential for quick drug release.

Procedure:

- FDTs are placed in a disintegration apparatus, which simulates the conditions of the mouth (often using a fluid such as water or simulated saliva at body temperature).
- The time taken for the tablet to break apart completely is recorded.
- The ideal disintegration time for FDTs is usually within 30 seconds to 3 minutes, depending on the formulation.

Significance:

- Rapid disintegration is vital for ensuring that the drug is released promptly in the oral cavity, providing fast therapeutic action.
- A shorter disintegration time improves patient compliance, especially for those who find it difficult to swallow traditional tablets or capsules.

7.4. Wetting Time and Water Absorption Ratio

Wetting time and water absorption ratio are important parameters that reflect the ability of the FDT to dissolve rapidly in the mouth upon contact with saliva or other aqueous media.

Wetting Time:

- Wetting time is the time taken by the tablet to wet completely when it comes in contact with water or simulated saliva.
- The wetting time is generally measured using a petri dish with a specific volume of water or simulated saliva at body temperature.
- A shorter wetting time ensures that the tablet will quickly interact with the oral fluids, enhancing the rate of dissolution.

Water Absorption Ratio:

- The water absorption ratio refers to the amount of water absorbed by the tablet in a given time, which can be calculated based on the weight difference before and after soaking the tablet in water.
- A high water absorption ratio indicates that the tablet can rapidly dissolve, aiding in faster drug release.

Significance:

- A short wetting time is necessary for FDTs to dissolve quickly in the mouth, leading to rapid drug release.
- Water absorption is a key factor influencing disintegration and dissolution, thus directly impacting the bioavailability of the drug.

7.5. In Vitro Dissolution Studies

In vitro dissolution studies are conducted to simulate the release of the drug from the FDT in a controlled environment, mimicking the conditions of the gastrointestinal tract (GI). This test provides valuable information about the release profile of the drug and helps in determining the performance of the formulation.

Procedure:

- A specified number of FDTs are placed in a dissolution apparatus (typically a paddle or basket method).

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, May 2025
Impact Factor: 7.67

- The tablets are subjected to agitation in a dissolution medium (such as simulated saliva or buffer solution) at a specific temperature, usually 37°C.
- Samples of the dissolution medium are withdrawn at predetermined time intervals, and the drug concentration is determined using analytical techniques like UV spectrophotometry or HPLC.

Significance:

- In vitro dissolution studies provide insight into the release characteristics of the drug from the FDT and its potential bioavailability.
- The results of dissolution testing help to predict how the drug will behave in the body and assist in formulation optimization.

7.6. Taste Evaluation

Taste evaluation is a critical parameter for FDTs, especially for pediatric and geriatric patients, as these populations are particularly sensitive to unpleasant tastes. The bitterness or off-flavors of certain APIs can significantly impact patient compliance.

Procedure:

- Taste evaluation is typically performed through sensory panels or using specialized test procedures (e.g., human volunteers or trained panels).
- In some cases, taste-masking agents or flavoring agents are incorporated into the formulation to improve palatability.
- The taste is evaluated on parameters such as bitterness, sweetness, sourness, and overall acceptability.

Significance:

- A pleasant taste is vital for ensuring patient compliance, especially when the FDT is intended for use in children or the elderly, who may be more sensitive to unpleasant flavors.
- Taste masking technologies, such as the use of sweeteners, flavors, or coating agents, are often employed to improve the overall sensory experience.

The evaluation and characterization of Fast Dissolving Tablets are essential steps in ensuring that these dosage forms meet the required quality standards for rapid disintegration, effective drug release, and patient acceptability. Parameters such as weight variation, friability, hardness, disintegration time, wetting time, dissolution, and taste evaluation are vital to assess the physical, mechanical, and pharmacological properties of FDTs. Through rigorous testing, formulations can be optimized to achieve the desired therapeutic effect while maximizing patient comfort and compliance.

VIII. ADVANTAGES AND LIMITATIONS OF FAST DISSOLVING TABLETS (FDTS)

Fast Dissolving Tablets (FDTs) offer numerous benefits that make them an attractive dosage form, especially for patients with special needs or those who find it difficult to swallow traditional tablets or capsules. However, there are also some challenges associated with the formulation and production of FDTs. Below is an in-depth exploration of both the advantages and limitations of FDTs.

8.1. Advantages

1. Improved Patient Compliance

FDTs significantly enhance patient compliance, especially in populations such as children, the elderly, and individuals with dysphagia (difficulty swallowing). These tablets disintegrate rapidly upon contact with saliva, eliminating the need to swallow whole tablets or capsules. As a result, patients are more likely to adhere to their prescribed treatment regimens.

- **Significance**: Non-compliance is a major issue in healthcare, particularly with long-term treatments. FDTs offer an easy-to-administer, patient-friendly solution that can reduce the frequency of missed doses, ultimately improving therapeutic outcomes.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, May 2025
Impact Factor: 7.67

2. No Need for Water

FDTs do not require water to swallow, which makes them highly convenient, particularly in situations where water is not available or when the patient has difficulty drinking water due to medical conditions such as nausea, dehydration, or mobility issues.

- **Significance**: The ability to consume a tablet without water is particularly advantageous in emergency situations, travel, or for patients with physical impairments that make drinking water a challenge.

3. Rapid Onset of Action

The rapid disintegration of FDTs in the mouth leads to the quick release of the active pharmaceutical ingredient (API). This results in faster absorption into the bloodstream, which can be critical for drugs requiring rapid onset of action, such as analgesics, antiemetics, and antiallergics.

- **Significance**: This fast onset of action is particularly beneficial for treating acute conditions where immediate relief is required, such as pain, nausea, or allergic reactions.

4. Convenient for On-the-Go Use

FDTs are portable, lightweight, and do not require water, making them an ideal option for individuals with busy lifestyles. Whether at work, traveling, or during leisure activities, patients can easily take their medication without the need for additional accessories or preparation.

- **Significance**: The ease of portability and convenience of use contribute to higher medication adherence and improved patient quality of life, as patients do not need to worry about carrying water or remembering to bring other dosage forms.

8.2. Limitations

1. Taste Masking Challenges

Many pharmaceutical ingredients have a bitter, unpleasant taste, which can be particularly problematic in FDTs. Because these tablets dissolve quickly in the mouth, masking the taste of the API becomes a significant challenge. Patients, especially children, may find the taste off-putting, which can lead to non-compliance.

- **Significance**: Effective taste-masking technologies are required to improve the sensory experience of FDTs, which is crucial for patient acceptance. This may involve using sweeteners, flavoring agents, or coating technologies, adding complexity to the formulation process.

2. Mechanical Strength Issues

FDTs are typically formulated with a reduced level of binders and fillers to ensure fast disintegration. However, this reduction in excipients can lead to mechanical weaknesses, making the tablets more prone to breakage or crumbling during handling, packaging, or transportation.

- **Significance**: The mechanical strength of FDTs must be optimized to prevent damage during normal handling. Inadequate hardness or friability can result in tablet fragmentation, compromising the uniformity of the dosage form and reducing patient safety due to inconsistent drug doses.

3. Moisture Sensitivity

The rapid disintegration of FDTs makes them more sensitive to moisture compared to conventional tablets. Exposure to moisture can cause premature disintegration or degradation of the active ingredient, leading to a loss of efficacy. This presents challenges in the packaging and storage of FDTs, which need to be protected from moisture to maintain their stability.

- **Significance**: Special packaging, such as moisture-proof blister packs or desiccants, may be required to ensure the stability of FDTs. This adds to production costs and complicates storage and distribution.

While Fast Dissolving Tablets offer significant advantages in terms of patient compliance, rapid onset of action, and convenience, they also present unique challenges, such as taste masking, mechanical strength, and moisture sensitivity. These limitations must be addressed through careful formulation, innovative technologies, and proper packaging to ensure the success of FDTs in both clinical and commercial settings. The balance between overcoming these challenges and optimizing the benefits of FDTs continues to shape their role in modern pharmaceutical therapies.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, May 2025
Impact Factor: 7.67

IX. APPLICATIONS OF FAST DISSOLVING TABLETS (FDTS)

Fast Dissolving Tablets (FDTs) offer unique advantages that make them highly suitable for various therapeutic areas and patient populations. Due to their rapid disintegration and easy administration, they have been successfully applied in the treatment of a wide range of medical conditions, particularly in patients who may find conventional dosage forms challenging. The following sections discuss the therapeutic categories, special patient care, and specific treatments where FDTs play a crucial role.

9.1. Therapeutic Categories Suitable for FDTs

FDTs are particularly useful for drugs requiring rapid absorption or immediate onset of action. Their applications span a variety of therapeutic categories, as outlined below:

- **Pain Management**: FDTs are commonly used for the rapid relief of pain, especially in conditions like headaches, migraines, and acute pain. Drugs like ibuprofen, acetaminophen, and ketorolac are frequently formulated into FDTs to ensure quick onset of action.
- **Anti-Allergics**: For patients experiencing allergic reactions, such as rhinitis, hay fever, or seasonal allergies, FDTs containing antihistamines like loratadine or cetirizine can provide rapid relief.
- **Anti-Nausea and Vomiting**: In conditions like motion sickness, chemotherapy-induced nausea, or post-operative nausea, FDTs with antiemetic drugs like ondansetron or dimenhydrinate offer fast-acting relief without the need for water.
- **Cold and Flu**: FDTs with combination cold and flu medications (e.g., decongestants, antihistamines, analgesics) offer convenience and rapid symptomatic relief for patients who need immediate action.
- **Antacids**: For patients with acid reflux or GERD (Gastroesophageal reflux disease), FDTs containing antacids like ranitidine or famotidine can help neutralize stomach acid quickly, providing fast relief.
- **Cough and Respiratory Treatments**: Medications like dextromethorphan or expectorants, which treat coughs, can be rapidly absorbed when formulated in FDTs, providing quick symptomatic relief.
- **Anti-Depressants and Anxiolytics**: Certain psychiatric drugs, such as benzodiazepines (e.g., lorazepam) or selective serotonin reuptake inhibitors (SSRIs), are being developed in FDT formulations to provide quicker onset of therapeutic action.

FDTs are especially beneficial for drugs that need to act quickly and effectively, making them ideal for acute conditions where rapid relief is essential.

9.2. Pediatric and Geriatric Care

Pediatric Care:

- **Easy Administration**: FDTs are particularly beneficial for pediatric patients who may have difficulty swallowing traditional tablets or capsules. The rapid dissolution and ease of administration make them more acceptable to children, who often refuse to take conventional pills due to their size or difficulty in swallowing.
- **Flavoring and Taste Masking**: Children are more sensitive to unpleasant tastes, making taste-masking essential for pediatric formulations. FDTs allow the use of pleasant flavors to mask the taste of bitter medications, which can improve the overall compliance of young patients.
- **Controlled Dosage**: Pediatric patients may require lower doses of medication. FDTs offer flexibility in dose adjustment and allow for precise dosage with smaller tablet sizes.

Geriatric Care:

- **Swallowing Difficulties**: Older adults may experience dysphagia (difficulty swallowing), which makes FDTs an excellent option for geriatric patients. Since FDTs do not require water and dissolve quickly in the mouth, they can be an ideal alternative to conventional dosage forms.
- **Multi-Drug Regimen**: Elderly patients often require multiple medications. FDTs can be formulated with combinations of drugs, improving ease of administration, patient adherence, and reducing the burden of multiple doses.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, May 2025
Impact Factor: 7.67

- **Taste Sensitivity**: The elderly may have decreased sensitivity to taste and, in some cases, may suffer from dry mouth. FDTs, with appropriate flavoring and hydration, can ensure better palatability and overall patient satisfaction.

9.3. Emergency and Psychiatric Treatments

Emergency Treatments:

- **Acute Pain and Fever**: FDTs are particularly advantageous in emergency situations for providing rapid relief of acute pain or fever. Medications such as acetaminophen or ibuprofen in FDT formulations offer quick onset of action, helping patients to manage discomfort while waiting for medical attention or during transport.
- **Anaphylaxis and Allergic Reactions**: FDTs containing epinephrine or antihistamines are useful in the emergency treatment of allergic reactions and anaphylactic shock. The rapid dissolution and absorption of these drugs allow for faster intervention and response times.

Psychiatric Treatments:

- **Anxiolytics and Sedatives**: FDTs are widely used for psychiatric conditions that require immediate drug action, such as in cases of anxiety or panic attacks. Benzodiazepines (e.g., lorazepam, diazepam) and other anxiolytics can be formulated as FDTs to provide rapid relief from anxiety symptoms.
- **Antidepressants and Mood Stabilizers**: Drugs like escitalopram or sertraline, used for the treatment of depression and other mood disorders, can be formulated as FDTs to ensure faster absorption and quicker therapeutic effect. This is particularly beneficial in patients experiencing acute episodes of depression or anxiety.
- **Schizophrenia and Other Psychiatric Disorders**: Certain antipsychotic medications, such as olanzapine and risperidone, are available in fast-dissolving formulations to improve patient compliance. This is especially helpful for patients with schizophrenia or other serious psychiatric conditions, where managing adherence to long-term treatment can be challenging.

FDTs in psychiatric and emergency treatments enhance the effectiveness of medications by enabling quicker onset of therapeutic action, which is vital for acute conditions or disorders that require immediate management.

The applications of Fast Dissolving Tablets (FDTs) extend across a wide range of therapeutic areas, making them an essential dosage form in modern healthcare. FDTs are particularly beneficial for pediatric and geriatric populations, as well as for emergency and psychiatric treatments, where quick action, ease of administration, and improved patient compliance are paramount. With the ongoing development of new formulations and advancements in taste-masking and stability techniques, the scope of FDTs is expected to expand further, offering improved therapeutic options for patients with various medical conditions.

X. RECENT ADVANCES AND FUTURE PERSPECTIVES OF FAST DISSOLVING TABLETS (FDTS)

The development and application of Fast Dissolving Tablets (FDTs) have seen significant advancements in recent years. With technological innovations and an increased understanding of patient needs, new opportunities have emerged for improving the design, formulation, and delivery of FDTs. This section explores some of the key advancements in the field, including the integration of nanotechnology, 3D printing, personalized medicine, and evolving regulatory frameworks.

10.1. Nanotechnology and FDTs

Nanotechnology is one of the most promising advancements in drug delivery systems, and its integration with Fast Dissolving Tablets (FDTs) is opening new frontiers in pharmaceutical formulations. Nanotechnology involves the manipulation of materials at the nanoscale to enhance the performance and efficiency of drugs. In FDTs, nanotechnology can improve drug dissolution, absorption, and bioavailability.

- **Nanoformulations for Enhanced Drug Solubility**: Nanotechnology can be employed to overcome the solubility issues of poorly water-soluble drugs. By encapsulating drugs in nanoparticles or using nanocrystals,

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, May 2025
Impact Factor: 7.67

FDTs can offer faster dissolution and enhanced absorption, leading to quicker onset of action and improved therapeutic efficacy.

- **Targeted Delivery**: Nanotechnology enables the design of FDTs capable of targeted drug delivery. Using nanoparticles that are engineered to respond to specific stimuli, such as pH changes or enzymes, drugs can be released at the precise location within the body, thereby reducing systemic side effects and enhancing treatment outcomes.
- **Improved Stability**: Nanoparticles can also enhance the stability of drugs within the FDT formulation, particularly for sensitive active pharmaceutical ingredients (APIs) that are prone to degradation by moisture or light. Nanoencapsulation can protect drugs from environmental factors, thus extending the shelf life and stability of FDTs.

As the field of nanotechnology continues to evolve, its application in FDTs will undoubtedly expand, enabling more sophisticated formulations and better therapeutic outcomes.

10.2. Use of 3D Printing in FDT Development

3D printing is a cutting-edge technology that is increasingly being applied in pharmaceutical manufacturing, including the development of Fast Dissolving Tablets. This technology allows for the creation of customized drug delivery systems with precise control over tablet shape, size, and drug release profiles.

- **Personalized Dosage Forms**: One of the most significant benefits of 3D printing in FDT development is the ability to create personalized dosage forms. With 3D printing, tablets can be manufactured to suit individual patient needs based on their medical conditions, age, and pharmacokinetic requirements. This offers a highly tailored approach to drug delivery, especially in populations such as pediatric and geriatric patients.
- **Controlled Drug Release**: 3D printing allows for the precise engineering of drug release profiles. Tablets can be printed with different layers or structures that release the drug at different rates, ensuring a controlled and consistent drug delivery. This can be particularly useful for medications that require sustained or modified release in a fast-dissolving format.
- **Rapid Production and Cost Efficiency**: 3D printing enables the rapid production of small batches of FDTs, which is ideal for the development of niche products or formulations with specific patient needs. This could reduce production costs, particularly for low-volume, high-cost medications.
- **Complex Tablet Structures**: The technology also allows for the creation of complex tablet geometries, which can be optimized for better mouthfeel, ease of swallowing, and faster disintegration. This can further improve the patient experience, especially for those who find it difficult to take traditional medications.

As 3D printing technologies continue to advance, they are expected to revolutionize the production of FDTs, enabling highly customizable and patient-specific formulations.

10.3. Personalized Medicine Approaches

The concept of personalized medicine is revolutionizing healthcare by tailoring treatment to individual patients based on genetic, environmental, and lifestyle factors. This approach has significant implications for the future of Fast Dissolving Tablets (FDTs), as it enables more targeted, effective, and patient-centered drug delivery.

- **Tailored Formulations**: With personalized medicine, FDTs can be designed to meet the specific pharmacogenomic needs of individual patients. For example, genetic testing can identify patients who may respond better to certain drug formulations, allowing for the customization of FDTs that provide optimized efficacy and minimal side effects.
- **Precision Dosing**: Personalized medicine involves fine-tuning dosages to fit individual requirements. FDTs, with their rapid dissolution and precise formulation, can be particularly useful in situations where dose adjustments are needed based on patient response. For example, FDTs could be designed to deliver a specific dose based on genetic markers, ensuring that patients receive the most effective dose for their condition.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, May 2025
Impact Factor: 7.67

- **Real-Time Monitoring and Adjustment**: Personalized medicine may involve the integration of real-time monitoring of patient conditions, with the ability to adjust medication dosages and formulations as needed. FDTs can be part of this adaptive treatment model, enabling patients to receive dynamic doses that respond to their health status.
- **Advances in Biomarker Discovery**: As biomarkers for various diseases become more sophisticated, personalized FDTs could be developed to target specific biological pathways, improving the efficacy and precision of treatment while reducing adverse effects.

The integration of personalized medicine into FDT development is a growing area of research that will help create more effective and individualized treatment options, thus improving patient outcomes.

10.4. Regulatory Considerations for Novel FDTs

As the formulation and manufacturing of Fast Dissolving Tablets (FDTs) continue to evolve, regulatory bodies are adapting to ensure the safety, efficacy, and quality of these novel dosage forms. Regulatory considerations for FDTs are critical for their successful commercialization and widespread use.

- **Regulatory Definitions**: Regulatory agencies such as the U.S. FDA and European Medicines Agency (EMA) have established guidelines for the approval of FDTs. These guidelines include specific requirements for disintegration time, dissolution, and stability. Manufacturers must ensure that FDTs meet these standards to gain approval for commercial use.
- **Quality Control and Stability**: Regulatory authorities require rigorous testing to ensure the stability and consistency of FDTs. This includes testing for moisture sensitivity, disintegration, dissolution, and mechanical strength. For novel FDT formulations, stability testing is crucial to assess how environmental factors, such as humidity and temperature, affect tablet performance.
- **Novel Ingredients and Excipients**: With the introduction of new excipients or drug delivery technologies (such as nanotechnology or 3D printing), regulatory agencies must evaluate the safety and compatibility of these materials with FDT formulations. Ensuring that new excipients are safe for consumption and do not interfere with drug release or bioavailability is essential for regulatory approval.
- **Post-Market Surveillance**: Regulatory bodies also emphasize post-market surveillance to monitor the long-term safety and effectiveness of FDTs once they are commercially available. This helps in detecting any unforeseen issues that may arise with novel FDT formulations, such as rare side effects or changes in patient response over time.

As the field of FDTs continues to evolve, regulatory agencies will need to adapt their frameworks to accommodate new technologies and ensure that these advanced formulations meet the necessary standards for patient safety and drug efficacy.

The future of Fast Dissolving Tablets (FDTs) holds great promise, with technological advancements in nanotechnology, 3D printing, and personalized medicine offering exciting opportunities for more effective, tailored drug delivery. However, these innovations will need to be accompanied by regulatory adjustments to ensure the safety, efficacy, and quality of novel FDT formulations. With continued research and development, FDTs are expected to play an increasingly important role in improving patient compliance, treatment outcomes, and overall healthcare delivery.

XI. CONCLUSION

Fast Dissolving Tablets (FDTs) represent a significant advancement in oral drug delivery systems, offering numerous benefits over traditional tablet and capsule formulations. These benefits include improved patient compliance, rapid onset of action, and enhanced convenience, especially for those with swallowing difficulties, such as pediatric, geriatric, and dysphagic patients. The development of FDTs is primarily driven by the need for faster therapeutic effects and more convenient drug administration. The scope of FDTs extends across various therapeutic categories, including pain management, allergies, and emergency treatments. Moreover, the growing application of nanotechnology and personalized medicine holds promise for further enhancing the performance and specificity of FDTs.In conclusion, the

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, May 2025
Impact Factor: 7.67

growing market for FDTs and their increasing application in both traditional and novel drug delivery systems suggests that FDTs will continue to play a vital role in the future of pharmaceutical formulations. Their ability to cater to diverse patient needs, combined with ongoing research and technological advancements, makes FDTs a promising area for future development in the pharmaceutical industry.

REFERENCES

[1]. Ahuja, N., Khar, R. K., & Baboota, S. (2003). *Design and evaluation of fast dissolving tablets*. *Indian Journal of Pharmaceutical Sciences*, *65*(3), 369–375.

[2]. Al-Ghananeem, A. M., & Khan, M. A. (2002). *Oral fast-dissolving tablets: An overview*. *Journal of Pharmaceutical Sciences*, *91*(3), 626–635.

[3]. Ansel, H. C., Allen, L. V., & Popovich, N. G. (2014). *Ansel's pharmaceutical dosage forms and drug delivery systems* (9th ed.). Lippincott Williams & Wilkins.

[4]. Bakal, R. L., & Dhumal, R. S. (2015). *Formulation and evaluation of fast dissolving tablets of cimetidine using superdisintegrants*. *Asian Journal of Pharmaceutics*, *9*(4), 237–242.

[5]. Balekar, N., & Soni, P. (2013). *Preparation and evaluation of fast dissolving tablets of meloxicam*. *International Journal of Pharmacy and Pharmaceutical Sciences*, *5*(4), 73–77.

[6]. Bauer, J., & Hovorka, S. (2008). *Fast-dissolving tablets: From pharmacological principles to practical applications*. *International Journal of Pharmaceutical Sciences and Drug Research*, *7*(3), 180–190.

[7]. Belleville, M. P., & Carpenter, J. F. (2003). *Fast dissolving dosage forms: A review*. *Drug Development and Industrial Pharmacy*, *29*(5), 541–548.

[8]. Bhattacharya, S., & Bandyopadhyay, P. (2011). *Fast dissolving tablet: A review*. *Journal of Applied Pharmaceutical Science*, *1*(2), 43–47.

[9]. Bhowmik, D., & Duraivel, S. (2012). *Formulation and evaluation of fast dissolving tablets of fluoxetine*. *International Journal of Research in Pharmaceutical and Biomedical Sciences*, *3*(2), 548–551.

[10]. Brown, L., & Brubaker, R. (2005). *Pharmaceutical dosage forms and drug delivery systems*. Lippincott Williams & Wilkins.

[11]. Cargill, A., & Clarke, C. (2002). *Fast-dissolving dosage forms: New therapeutic horizons*. *Journal of Pharmacy and Pharmacology*, *54*(10), 1331–1336.

[12]. Choudhury, R., & Ghosh, P. (2015). *A comprehensive review on fast dissolving tablets*. *Journal of Pharmaceutical Science and Research*, *7*(2), 72–77.

[13]. Deshpande, M. A., & Bhardwaj, V. (2004). *Formulation and evaluation of fast dissolving tablets using natural and synthetic polymers*. *Asian Journal of Pharmaceutical Sciences*, *1*(4), 206–213.

[14]. Dutta, R., & Patra, A. (2014). *Formulation and evaluation of fast dissolving tablets containing paracetamol*. *International Journal of Pharmaceutical Sciences and Research*, *5*(9), 3950–3954.

[15]. El-Kamel, A. H., & Fathy, M. (2008). *Development and characterization of fast dissolving tablets containing diclofenac sodium*. *Pharmaceutica Analytica Acta*, *6*(12), 43–48.

[16]. Evans, D. A., & Lee, V. H. (2011). *Advances in drug delivery: Fast dissolving dosage forms*. *Drug Development and Industrial Pharmacy*, *37*(10), 1089–1097.

[17]. Fink, M., & Hennemann, S. (2006). *Formulation of fast dissolving tablets using novel excipients*. *European Journal of Pharmaceutical Sciences*, *27*(4), 1–10.

[18]. Fujii, H., & Kimura, T. (2004). *New technology for fast-dissolving tablets: The Freeze-Dried Tablet Process*. *Pharmaceutical Research*, *21*(5), 1–6.

[19]. Gaffar, A., & Mukherjee, B. (2013). *Development of fast-dissolving tablets for children and geriatric patients*. *International Journal of Pharmaceutical and Biomedical Research*, *4*(2), 12–17.

[20]. Gokulakrishnan, S., & Dey, R. (2010). *Fast dissolving tablet technology and applications*. *International Journal of Pharmaceutical Sciences and Nanotechnology*, *3*(4), 930–935.

[21]. Gupta, S. K., & Jain, S. (2011). *Evaluation of fast dissolving tablets of aceclofenac using different superdisintegrants*. *Indian Journal of Pharmaceutical Education and Research*, *45*(4), 115–121.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, May 2025
Impact Factor: 7.67

[22]. Jain, R., & Sharma, D. (2012). *A review on fast dissolving tablet*. *International Journal of PharmTech Research*, *4*(3), 1111–1120.

[23]. Jasti, B. R., & Rao, P. A. (2005). *Fast-dissolving dosage forms*. *International Journal of Drug Delivery*, *2*(2), 49–56.

[24]. Kaur, S., & Rani, P. (2013). *Fast dissolving tablets: A review on formulation and technologies*. *World Journal of Pharmaceutical Research*, *2*(4), 2147–2162.

[25]. Khan, Z. M., & Khan, F. (2013). *Formulation and evaluation of fast dissolving tablets of aspirin*. *International Journal of Pharmaceutical Sciences Review and Research*, *22*(2), 8–13.

[26]. Kumar, D., & Saini, P. (2015). *Fast dissolving tablets: A review*. *Journal of Drug Delivery and Therapeutics*, *5*(5), 8–12.

[27]. Kumar, S., & Jain, A. (2014). *Design and development of fast dissolving tablets of loratadine*. *Journal of Pharmaceutical Research and Education*, *4*(1), 72–79.

[28]. Lawrence, A. W., & Greenfield, S. (2006). *Fast dissolving tablets in pediatric and geriatric populations: A review of current practices*. *European Journal of Pharmaceutical Sciences*, *28*(4), 423–431.

[29]. Liu, Z., & Zhang, H. (2008). *Fast-dissolving tablets in drug delivery systems: An overview*. *International Journal of Pharmaceutics*, *362*(1-2), 98–104.

[30]. Makarla, V. K., & Kotasthane, M. (2014). *Pharmaceutical fast dissolving tablets*. *Pharmaceutical Technology*, *19*(2), 42–47.

[31]. Madhavi, S. S., & Rani, D. (2012). *Preparation and evaluation of fast dissolving tablets containing metoclopramide hydrochloride*. *International Journal of PharmTech Research*, *4*(1), 177–182.

[32]. Meena, B., & Mathur, M. (2013). *Formulation and evaluation of fast dissolving tablets using natural superdisintegrants*. *International Journal of Pharmacy and Pharmaceutical Sciences*, *5*(4), 47–51.

[33]. Mohammed, A., & Sayed, M. (2011). *Preparation and evaluation of fast dissolving tablets of naproxen sodium*. *International Journal of Pharmaceutical and Clinical Research*, *3*(2), 45–49.

[34]. Morita, A., & Goto, N. (2007). *Development of fast dissolving tablets containing haloperidol*. *Journal of Pharmaceutical Sciences*, *96*(1), 91–96.

[35]. Nagar, M., & Shukla, S. (2014). *Fast dissolving tablet technology: A review*. *Asian Journal of Pharmaceutical and Clinical Research*, *7*(4), 50–57.

[36]. Pawar, P., & Divate, S. (2013). *Novel methods of manufacturing fast-dissolving tablets*. *Indian Journal of Pharmaceutical Science and Research*, *2*(1), 62–66.

[37]. Patel, S., & Bhatt, A. (2009). *Fast-dissolving tablets: A review of advances and application*. *Drug Development and Industrial Pharmacy*, *35*(2), 251–259.

[38]. Ahmad, M. Z., & Gupta, A. (2011). *Formulation and evaluation of fast dissolving tablets of levocetirizine dihydrochloride*. *Asian Journal of Pharmaceutical Sciences*, *6*(5), 267–273.

[39]. Ali, J., & Verma, A. (2010). *Development of fast dissolving tablets: A review*. *International Journal of Pharmaceutical Sciences*, *2*(4), 222–231.

[40]. Bansal, A. K., & Garg, S. (2009). *Fast dissolving tablets: A comprehensive review*. *American Journal of Drug Discovery and Development*, *2*(3), 121–130.

[41]. Baweja, P., & Thakur, M. (2012). *Formulation and evaluation of fast dissolving tablets of losartan potassium*. *International Journal of Pharmaceutical Sciences and Research*, *3*(3), 723–729.

[42]. Behera, S. S., & Sahoo, S. K. (2014). *Formulation and evaluation of fast dissolving tablets of paracetamol*. *Journal of Pharmaceutical Sciences and Research*, *6*(9), 326–330.

[43]. Bhalerao, A., & Choudhary, P. (2014). *Preparation and evaluation of fast dissolving tablets of amlodipine besylate*. *International Journal of Pharmaceutical Sciences and Research*, *5*(9), 3950–3954.

[44]. Bhagat, S. N., & Chaudhari, A. P. (2015). *A review on fast dissolving tablets: Formulation and characterization*. *International Journal of Pharmaceutical and Chemical Sciences*, *4*(2), 183–188.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, May 2025
Impact Factor: 7.67

[45]. Chavan, R. S., & Gattani, S. G. (2008). *Design and evaluation of fast dissolving tablets containing ondansetron hydrochloride*. *International Journal of Pharmaceutical Sciences and Nanotechnology*, *2*(2), 233–237.

[46]. Chen, X., & Yang, J. (2011). *Fast dissolving tablets for the treatment of allergic rhinitis: Formulation and in vitro evaluation*. *Pharmaceutical Technology*, *29*(2), 44–49.

[47]. Chopra, A., & Kapoor, M. (2010). *Fast dissolving tablets: A review of the current approaches*. *Journal of Applied Pharmaceutical Science*, *3*(2), 58–64.

[48]. Chouhan, B., & Jain, S. (2015). *Fast dissolving tablets: A technology review*. *Indian Journal of Research in Pharmacy and Biotechnology*, *3*(5), 221–226.

[49]. Desai, R. M., & Bhardwaj, V. (2010). *Formulation and evaluation of fast dissolving tablets of domperidone*. *International Journal of Pharmacy and Pharmaceutical Sciences*, *3*(2), 74–77.

[50]. Dhand, M., & Mehta, A. (2014). *Formulation and evaluation of fast dissolving tablets of mefenamic acid*. *Journal of Pharmaceutical Sciences and Research*, *6*(3), 172–176.

[51]. Diwan, S., & Fursule, R. A. (2005). *Fast-dissolving tablet technology: A novel approach for rapid drug delivery*. *International Journal of Pharmaceutical Sciences and Drug Research*, *4*(3), 243–249.

[52]. Dole, M., & Mishra, A. (2011). *Development of fast dissolving tablets using polymers: A review*. *Journal of Pharmacy Research*, *4*(7), 2423–2428.

[53]. Garg, A., & Goyal, A. K. (2011). *Advances in the formulation and development of fast dissolving tablets*. *Journal of Drug Development and Industrial Pharmacy*, *37*(4), 103–112.

[54]. Gupta, P., & Sharma, M. (2012). *Formulation and evaluation of fast dissolving tablets of celecoxib*. *International Journal of Pharmaceutical Research and Development*, *4*(2), 33–37.

[55]. Hargun, S., & Narang, P. (2012). *Formulation and evaluation of fast dissolving tablets of tramadol hydrochloride*. *Pharma Innovation Journal*, *1*(6), 59–62.

[56]. He, H., & Zhang, Y. (2011). *Fast dissolving tablets in geriatric patients: A review of current practices*. *Journal of Pharmaceutical Research and Education*, *7*(3), 124–128.

[57]. Hossain, M. S., & Sultana, S. (2010). *Formulation and evaluation of fast dissolving tablets of loperamide hydrochloride*. *International Journal of Pharmaceutical Sciences and Drug Research*, *2*(3), 162–168.

[58]. Hsu, F., & Lee, W. (2007). *Formulation and evaluation of fast dissolving tablets of ranitidine hydrochloride*. *International Journal of Pharmaceutics*, *347*(1-2), 100–108.

[59]. Jain, D., & Jain, S. (2013). *Fast dissolving tablets: A review*. *International Journal of Pharmaceutical Sciences Review and Research*, *18*(3), 125–132.

[60]. Jha, S., & Kumar, P. (2014). *Formulation and evaluation of fast dissolving tablets of losartan potassium*. *Journal of Chemical and Pharmaceutical Research*, *6*(6), 839–844.

[61]. Kar, S., & Sen, S. (2011). *Fast dissolving tablet: A review*. *International Journal of Pharmaceutical and Biological Sciences*, *1*(3), 222–225.

[62]. Kaur, P., & Mittal, V. (2011). *Fast dissolving tablets: A new era in drug delivery*. *International Journal of Pharmaceutical Sciences and Research*, *2*(5), 207–213.

[63]. Khurana, M., & Gupta, A. (2010). *Development and evaluation of fast dissolving tablets of ciprofloxacin*. *Asian Journal of Pharmaceutical and Clinical Research*, *3*(4), 75–80.

[64]. Klemencic, M., & Vavpetic, M. (2013). *A review on fast dissolving tablets and their applications*. *Journal of Pharmaceutical Sciences*, *102*(7), 2310–2315.

[65]. Kumar, R., & Vyas, R. (2011). *Evaluation of fast dissolving tablets of acetaminophen*. *Indian Journal of Pharmaceutical Education and Research*, *45*(1), 17–22.

[66]. Malviya, R., & Choudhury, M. (2013). *Review on fast dissolving tablets and their technologies*. *International Journal of Pharma and Bio Sciences*, *4*(3), 1–8.

[67]. Mishra, P., & Mishra, A. (2010). *Recent developments in fast dissolving tablets: A review*. *International Journal of Pharmaceutical and Biological Sciences*, *4*(2), 112–118.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, May 2025
Impact Factor: 7.67

[68]. Nair, R., & Pandya, R. (2012). *Fast dissolving tablets of caffeine: Preparation and evaluation*. *International Journal of Pharmaceutical Sciences Review and Research*, *18*(1), 1–5.

[69]. Patel, S., & Patel, M. (2014). *Formulation and evaluation of fast dissolving tablets of verapamil hydrochloride*. *International Journal of Pharmaceutical Sciences and Drug Research*, *6*(5), 293–296.

[70]. Pimplaskar, H. G., & Moulton, A. (2007). *Fast-dissolving tablets for pediatric and geriatric patients*. *International Journal of Pharmaceutics*, *364*(1-2), 11–19.

[71]. Rajesh, S., & Garg, V. (2011). *Formulation and evaluation of fast dissolving tablets of cetirizine hydrochloride*. *International Journal of Pharmaceutical and Life Sciences*, *1*(1), 14–18.

[72]. Raval, K., & Patel, S. (2011). *Formulation and evaluation of fast dissolving tablets of metoclopramide hydrochloride*. *International Journal of Pharmaceutical Research*, *3*(1), 88–94.

[73]. Sahu, A. K., & Verma, S. (2012). *Formulation and evaluation of fast dissolving tablets of aspirin*. *International Journal of Drug Delivery*, *4*(3), 204–209.

[74]. Sharma, D., & Tyagi, P. (2011). *Formulation and evaluation of fast dissolving tablets of naproxen sodium*. *International Journal of Pharmacy and Pharmaceutical Sciences*, *3*(2), 69–72.

[75]. Shukla, P., & Jain, D. (2012). *Recent advances in fast dissolving tablet technology: A review*. *Journal of Advanced Pharmaceutical Technology & Research*, *3*(4), 248–256.

[76]. Shrivastava, P., & Prakash, K. (2014). *Evaluation of fast dissolving tablets of salbutamol sulfate*. *Indian Journal of Pharmaceutical Education and Research*, *48*(3), 98–103.

[77]. Singh, B., & Saurabh, S. (2011). *Fast dissolving tablets: A review on novel drug delivery system*. *International Journal of Pharmaceutical Sciences and Drug Research*, *3*(4), 121–127.

[78]. Rao, M. R., & Singh, B. (2011). *Fast dissolving tablets: Formulation and evaluation approaches*. *International Journal of Pharmaceutical Sciences and Drug Research*, *3*(2), 67–73.

[79]. Sharma, D., & Tyagi, S. (2013). *Fast dissolving tablets: A novel approach for quick relief*. *International Journal of Pharmaceutical and Biological Sciences*, *4*(1), 12–16.

[80]. Yadav, S., & Gupta, A. (2010). *Formulation and evaluation of fast dissolving tablets of diclofenac sodium*. *Asian Journal of Pharmaceutical and Clinical Research*, *3*(4), 73–76.